oral glp-1 agonist Small-Molecule Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies The development of an oral

In a study comparing the effects of semaglutide and tirzepatide for weight loss, those receiving tirzepatide were more likely to achieve 5% or greater, 10% or greater, and 15% or greater weight loss and experienced larger reductions in body weight at 3, 6, and 12 months

Front Endocrinol (Lausanne) 10:260 Muller TD et al (2019) Glucagon-like peptide 1 (GLP-1)

doi: 10.3389/FENDO.2024.1431292 48 MollHFreyEGerberPGeidlBKaufmannMBraunJet al

Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis

Others have moved in the opposite direction, limiting coverage due to budget concerns